Table 2 Evaluation of the markers using the validation set with 16 non-lepidic AD and 11 PDSCC patients

AD markers

(Marker status)

Sensitivity

Specificity

PPV

NPV

Accuracy

(subtype)

AD

SCC

AD

SCC

(95 % CI†)

(95 % CI)

(95 % CI)

(95 % CI)

(95 % CI)

ST6GALNAC1*

15

0

1

11

0.938

(0.698–0.998)

1.000

(0.715–1.000)

1.000

(0.782–1.000)

0.917

(0.615–0.998)

0.963

(0.810–0.999)

TTF-1

10

0

6

11

0.625

(0.354–0.848)

1.000

(0.715–1.000)

1.000

(0.692–1.000)

0.647

(0.383–0.858)

0.778

(0.577–0.914)

napsin A

12

0

4

11

0.750

(0.476–0.927)

1.000

(0.715–1.000)

1.000

(0.735–1.000)

0.733

(0.449–0.922)

0.852

(0.663–0.958)

SCC markers

(Marker status)

Sensitivity

Specificity

PPV

NPV

Accuracy

(subtype)

SCC

AD

SCC

AD

(95 % CI)

(95 % CI)

(95 % CI)

(95 % CI)

(95 % CI)

SPATS2*

7

0

4

16

0.636

(0.308–0.891)

1.000

(0.794–1.000)

1.000

(0.590–1.000)

0.800

(0.563–0.943)

0.852

(0.663–0.958)

CK5

7

0

4

16

0.636

(0.308–0.891)

1.000

(0.794–1.000)

1.000

(0.590–1.000)

0.800

(0.563–0.943)

0.852

(0.663–0.958)

DSG3

6

0

5

16

0.545

(0.234–0.833)

1.000

(0.794–1.000)

1.000

(0.541–1.000)

0.762

(0.528–0.918)

0.815

(0.619–0.937)

p40

7

0

4

16

0.636

(0.308–0.891)

1.000

(0.794–1.000)

1.000

(0.590–1.000)

0.800

(0.563–0.943)

0.852

(0.663–0.958)

CK6

5

9

6

7

0.455

(0.167–0.766)

0.438

(0.198–0.701)

0.357

(0.128–0.649)

0.538

(0.251–0.808)

0.444

(0.255–0.647)